髓源性抑制细胞在膀胱癌中的作用：一个新兴的靶点。
Myeloid-Derived Suppressor Cells in Bladder Cancer: An Emerging Target.
机构信息
CNRS UMR 5164, ImmunoConcEpT, Biological and Medical Sciences Department, University of Bordeaux, 146 rue Léo Saignat, 33000 Bordeaux, France.
Department of Urology, University Hospital of Bordeaux, 33000 Bordeaux, France.
出版信息
Cells. 2024 Oct 27;13(21):1779. doi: 10.3390/cells13211779.
Bladder cancer remains a prevalent and challenging malignancy. Myeloid-derived suppressor cells (MDSCs) have emerged as key contributors to the immunosuppressive tumor microenvironment, facilitating tumor progression, immune evasion, and resistance to therapies. This review explores the role of MDSC in bladder cancer, highlighting their involvement in immune regulation; tumor progression; and resistance to therapies such as bacillus Calmette-Guérin (BCG) therapy, chemotherapy, and immune checkpoint inhibitors (ICIs). We also discuss their potential as biomarkers and therapeutic targets, with current evidence suggesting that targeting MDSCs, either alone or in combination with existing treatments such as BCG and ICIs, may enhance anti-tumor immunity and improve clinical outcomes. However,, challenges remain, particularly regarding the identification and therapeutic modulation of MDSC subpopulations. Further research is warranted to fully elucidate their role in bladder cancer and to optimize MDSC-targeted therapies.
膀胱癌仍然是一种普遍存在且具有挑战性的恶性肿瘤。髓系来源的抑制性细胞（MDSC）已成为免疫抑制性肿瘤微环境的主要贡献者，促进肿瘤进展、免疫逃逸和对治疗的耐药性。本综述探讨了 MDSC 在膀胱癌中的作用，强调了它们在免疫调节、肿瘤进展以及对卡介苗（BCG）治疗、化疗和免疫检查点抑制剂（ICI）等治疗的耐药性中的参与。我们还讨论了它们作为生物标志物和治疗靶点的潜力，目前的证据表明，单独靶向 MDSC 或与 BCG 和 ICI 等现有治疗联合靶向 MDSC，可能增强抗肿瘤免疫并改善临床结果。然而，仍存在挑战，特别是在 MDSC 亚群的鉴定和治疗调节方面。需要进一步的研究来充分阐明它们在膀胱癌中的作用，并优化 MDSC 靶向治疗。
Zotero 插件